• Clinical Study Data

    The Minerva System has been clinically tested in rigorous studies for FDA approval. One year after treatment, patients reported significantly reduced menstrual bleeding with a Success Rate of 92% (bleeding reduced to normal level), and Amenorrhea Rate of 66% (not even one drop of blood).

The Minerva FDA Pivotal Trial was a Single-Arm Study comparing the Minerva System to an Objective Performance Criteria (OPC) established by the FDA. The OPC of 66% combines the Success Rates of the 5 previously FDA approved GEA devices.

Her Option67%

Minerva Endometrial Ablation System

Success Rate: 92% | Amenorrhea Rate: 66%

Patient Satisfaction98%
Would Recommend99%
Reduction in PMS81%
Reduction in Dysmenorrhea55%

Download IFU

Please complete the fields below to get access to our IFU, Operation Manual and Publications.

[contact-form-7 404 "Not Found"]"]

Operator’s Manual

[contact-form-7 404 "Not Found"]"]